BDSX

SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on behalf of Biodesix, Inc. (NASDAQ: BDSX) investors following the Company's sharp stock decline on November 6, 2026. The investigation concerns whether Biodesix, a Louisville, Colorado-based diagnostic solutions company, or its officers made materially false or misleading statements or failed to disclose material information to investors.

CSBR and BDSX ride on distinct oncology growth drivers, but which stock looks more compelling amid contrasting performance and valuations? Let's dive in.

LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming investor conferences:

Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biodesix (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.